Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is characterized by profound immunosuppression.
• Natural killer (NK) cell function is impaired in CLL patients due to dysregulated activating and inhibitory receptors.

Purpose of the Study:

• To investigate the role of the inhibitory receptor Ig-like transcript 2 (ILT2) in regulating NK cells in CLL.
• To evaluate the therapeutic potential of lenalidomide and ILT2 blockade in CLL.

Main Methods:

• Analysis of ILT2 expression on leukemic and NK cells in CLL patients.
• Assessment of lenalidomide's effect on ILT2 and its ligands.
• Evaluation of NK cell activation, proliferation, and cytotoxicity following ILT2 blockade and lenalidomide treatment.

Main Results:

• ILT2 expression was decreased on CLL cells and increased on NK cells, correlating with advanced disease and poor prognostic features.
• Lenalidomide increased ILT2 expression and partially restored its ligands on CLL cells.
• Lenalidomide enhanced NK cell activation and proliferation, further augmented by ILT2 blockade.
• Combined ILT2 blockade and lenalidomide increased NK cell cytotoxicity, leading to greater elimination of CLL cells.

Conclusions:

• ILT2 plays a role in NK cell suppression in CLL.
• ILT2 blockade combined with lenalidomide represents a potential therapeutic strategy for CLL by restoring NK cell activity.